Literature DB >> 31740047

Molecular docking, antiproliferative and anticonvulsant activities of swertiamarin isolated from Enicostemma axillare.

Jaishree Vaijanathappa1, Jamuna Puttaswamygowda2, Ramesh Bevanhalli2, Sheshagiri Dixit3, Prabitha Prabhakaran3.   

Abstract

Present study aimed for molecular docking, antiproliferative and anticonvulsant activities of swertiamarin isolated from the successive methanol extract of Enicostemma axillare. Molecular docking of swertiamarin on telomerase targets (PDB ID: 5UGW, 3DU6 and 4ERD), followed by antiproliferative activity on HEp2 and HT-29 cells by MTT and SRB assays. Also tested for anticonvulsant activity by pentylenetetrazole (PTZ, 80 mg/kg bw) induced convulsant. Molecular docking study predicted good total score of the swertiamarin with the selected targets. Swertiamarin possesses antiproliferative activity on HEp-2 and HT-29 cells with lower CTC50 values. It also served as significant anticonvulsant agent with prolonged onset and reduced duration of the seizures. These results confirm that swertiamarin exhibited potential antiproliferative and anticonvulsant activities.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticonvulsant activity; Cytotoxicity; Molecular docking; Swertiamarin

Mesh:

Substances:

Year:  2019        PMID: 31740047     DOI: 10.1016/j.bioorg.2019.103428

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  2 in total

1.  Novel ACE Inhibitory Peptides Derived from Simulated Gastrointestinal Digestion in Vitro of Sesame (Sesamum indicum L.) Protein and Molecular Docking Study.

Authors:  Ruidan Wang; Xin Lu; Qiang Sun; Jinhong Gao; Lin Ma; Jinian Huang
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

2.  Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin - A Promising Natural Lead for New Drug Discovery and Development.

Authors:  Nur Sakinah Muhamad Fadzil; Mahendran Sekar; Siew Hua Gan; Srinivasa Reddy Bonam; Yuan Seng Wu; Jaishree Vaijanathappa; Subban Ravi; Pei Teng Lum; Shivsharan B Dhadde
Journal:  Drug Des Devel Ther       Date:  2021-06-21       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.